Perspective Therapeutics ...

AMEX: CATX · Real-Time Price · USD
3.58
-0.32 (-8.21%)
At close: Aug 15, 2025, 3:59 PM
3.61
0.98%
After-hours: Aug 15, 2025, 05:40 PM EDT

Perspective Therapeutics Income Statement

Financials in USD. Fiscal year is July - June.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
234K 342K n/a n/a n/a n/a 337K 1.91M 1.5M 1.83M 1.83M 1.72M 2.5M 2.91M 2.82M 2.56M 2.71M 2.6M
Cost of Revenue
709K 732K n/a n/a n/a n/a n/a 1.45M 1.84M 1.58M 1.43M 1.3M 1.58M 1.47M 1.6M 1.53M 1.36M 1.24M
Gross Profit
-475K -390K n/a n/a n/a n/a 337K 462K -340K 254K 403K 414K 926K 1.44M 1.22M 1.03M 1.35M 1.36M
Operating Income
-20.89M -21.83M -44.98M -18.63M -14.26M -13.01M -7.81M -10.53M -11.37M -11.21M -3.2M -4.21M -2.11M -1.21M -1.64M -2.27M -1.09M -766K
Interest Income
2.65M 2.38M 2.65M 3.58M 3.08M 1.21M 62K 204K 294K 374K 400K 140K 28K 29K 31K 31K 32K 21K
Pretax Income
-42.21M -18.18M -42.27M -15.12M -11.28M -11.82M -8.87M -10.08M -11.11M -10.87M -2.9M -4.07M -2.08M -1.35M -1.6M -2.24M -1.06M -745K
Net Income
-40.17M -18.18M -40.17M -15.12M -11.7M -12.28M -24.68M -10.36M -11.11M -371K -2.2M -3.93M -2.01M -1.21M -1.6M -2.24M -1.06M -745K
Selling & General & Admin
8.25M 7.84M 8.25M 6.97M 5.51M 5.88M 1.69M 5.55M 5.98M 7.83M 2.99M 3.91M 2.24M 2.27M 2.32M 2.6M 1.97M 1.76M
Research & Development
12.17M 14.33M 12.88M 12.03M 9.28M 7.45M 6.08M 5.72M 5.65M 3.86M 613K 708K 796K 549K 535K 702K 468K 362K
Other Expenses
n/a -342K 23.86M n/a n/a -325K -5.21M n/a 2K -233K n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
20.42M 21.83M 46.44M 18.63M 14.26M 13.01M 2.57M 11M 11.03M 11.46M 3.61M 4.62M 3.03M 2.82M 2.85M 3.3M 2.44M 2.13M
Interest Expense
-119K 128K -73K 69K 23K 29K 24K 14K 26K 18K 400K 140K n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a -2.58M 855K 911K 812K 814K 800K 654K 687K 702K 761K 659K 581K
Cost & Expenses
21.13M 21.83M 45.22M 18.63M 14.26M 13.01M 2.57M 12.44M 12.87M 13.04M 5.04M 5.92M 4.61M 4.29M 4.45M 4.84M 3.8M 3.36M
Income Tax Expense
-2.1M n/a -2.1M n/a -61K n/a 7.85M 278K -215K -10.5M -702K -140K -65K -140K -28K -29K -574K -31K
Shares Outstanding (Basic)
70.67M 72.36M 70.63M 70.63M 66.65M 49.51M 54.91M 54.91M 54.91M 54.91M 54.91M 54.91M 54.91M 54.91M 54.91M 54.91M 54.91M 54.91M
Shares Outstanding (Diluted)
70.67M 72.36M 70.63M 70.63M 66.65M 49.51M 54.91M 54.91M 54.91M 54.91M 54.91M 54.91M 54.91M 54.91M 54.91M 54.91M 54.91M 54.91M
EPS (Basic)
-0.57 -0.25 -0.57 -0.21 -0.18 -0.25 -0.45 -0.19 -0.2 -0.01 -0.04 -0.07 -0.04 -0.02 -0.03 -0.04 -0.02 -0.01
EPS (Diluted)
-0.57 -0.25 -0.57 -0.21 -0.18 -0.25 -0.45 -0.19 -0.2 -0.01 -0.04 -0.07 -0.04 -0.02 -0.03 -0.04 -0.02 -0.01
EBITDA
-41.5M -17.32M -43.96M -14.38M -10.68M -11.44M -8.58M -9.81M -11.08M -10.65M -3.1M -4.21M -2.11M -1.38M -1.64M -2.21M -1.09M -762K
EBIT
-42.21M -18.05M -42.34M -15.05M -11.25M -11.79M -8.85M n/a -11.37M -11.21M -3.2M n/a n/a -1.21M n/a -2.27M n/a n/a
Depreciation & Amortization
709K 732K 721K 669K 570K 346K 262K 259K 245K 554K 98K 68K 65K -169K 60K 59K 42K 36K